GlassScriptPhysician profile
Saima Usmani
NPI 1669933800
$1,598.15
in general payments reported to CMS, 2019-2025
25 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $391 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211.66 | 2024-2025 | |
| Eisai INC. | $180.53 | 2024-2025 | |
| Ucb, INC. | $131.79 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $114.01 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biogen, INC. | $113.86 | 2024-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $89.48 | 2025 | Kisunla |
| Neurocrine Biosciences, INC. | $79.67 | 2024-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $76.93 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $73.03 | 2025 | Onpattro |
| Neurelis, INC. | $68.77 | 2024-2025 | Valtoco |
| Argenx US, INC. | $67.68 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $58.67 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.25 | 2025 | |
| Lundbeck LLC | $53.17 | 2024-2025 | Rexulti |
| Pfizer INC. | $35.21 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.61 | 2025 | Uplizna |
| Inspire Medical Systems, INC. | $23.12 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $19.30 | 2024 | Rexulti |
| Merz Pharmaceuticals, LLC | $18.26 | 2024 | Xeomin |
| Azurity Pharmaceuticals, INC. | $17.66 | 2025 | Horizant |
| Jazz Pharmaceuticals INC. | $17.64 | 2024 | |
| Acadia Pharmaceuticals INC | $16.00 | 2025 | Nuplazid |
| Boston Scientific Corporation | $15.62 | 2024 | |
| Janssen Biotech, INC. | $15.51 | 2024 | Tremfya |
| Life Molecular Imaging LTD | $13.72 | 2024 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Usmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.